Edition:
United Kingdom

Prothena Corporation PLC (PRTA.OQ)

PRTA.OQ on NASDAQ Stock Exchange Global Select Market

14.85USD
20 Jul 2018
Change (% chg)

$-0.20 (-1.33%)
Prev Close
$15.05
Open
$15.05
Day's High
$15.17
Day's Low
$14.75
Volume
78,464
Avg. Vol
291,921
52-wk High
$70.00
52-wk Low
$10.44

Latest Key Developments (Source: Significant Developments)

Prothena Sees $9 Mln-$13 Mln Restructuring Charges In Q2
Friday, 25 May 2018 

May 25 (Reuters) - Prothena Corporation PLC ::PROTHENA CORP SAYS $9 MILLION-$13 MILLION RESTRUCTURING CHARGES RELATED TO WORKFORCE REDUCTION EXPECTED TO BE INCURRED IN Q2 2018 - SEC FILING.  Full Article

Prothena Announces Reorganization To Focus Resources On Advancing Neuroscience Pipeline
Thursday, 24 May 2018 

May 24 (Reuters) - Prothena Corporation PLC ::PROTHENA ANNOUNCES REORGANIZATION TO FOCUS RESOURCES ON ADVANCING NEUROSCIENCE PIPELINE.PROTHENA CORPORATION PLC - INITIATED A REORGANIZATION TO ALIGN ITS RESOURCES ON ADVANCING ITS BROAD NEUROSCIENCE PIPELINE.PROTHENA CORPORATION PLC - FOLLOWING REORGANIZATION EXPECTS ITS WORKFORCE TO BE APPROXIMATELY 63 POSITIONS..PROTHENA CORPORATION PLC - COMPANY IS REVISING ITS FULL YEAR 2018 FINANCIAL GUIDANCE.PROTHENA CORPORATION PLC - EXPECTS 2018 NET CASH BURN FROM OPERATING & INVESTING ACTIVITIES TO BE $40 TO $50 MILLION.PROTHENA CORPORATION PLC - AS A RESULT OF DISCONTINUATION OF NEOD001 DEVELOPMENT PROGRAM, WILL REDUCE WORKFORCE BY ABOUT 57 PERCENT.PROTHENA - ESTIMATED 2018 NET LOSS INCLUDES $80 TO $85 MILLION OF OPERATING EXPENSES ASSOCIATED WITH NEOD001 AND REORGANIZATION.PROTHENA - REORGANIZATION INCLUDES ONGOING CLINICAL-STAGE PROGRAMS FOR PRX002/RG7935, PROPRIETARY PROGRAM PRX004 DISCOVERY-STAGE PIPELINE.PROTHENA - REORGANIZATION INCLUDES DISCOVERY-STAGE PIPELINE, 3 PROGRAMS BEING ADVANCED UNDER COLLABORATION WITH CELGENE.  Full Article

Prothena reports Q3 loss per share $1.37
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Prothena Corporation Plc ::Prothena reports third quarter 2017 financial results and provides research and development update.Q3 loss per share $1.37.Q3 revenue $200,000.Q3 revenue view $251,000 -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-1.39 -- Thomson Reuters I/B/E/S.  Full Article

Prothena reports third quarter financial results
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Prothena Corporation Plc :Prothena reports third quarter 2017 financial results and provides research and development update.Q3 loss per share $1.37.Q3 revenue $200,000.Q3 revenue view $251,000 -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-1.39 -- Thomson Reuters I/B/E/S.  Full Article

Prothena reports Q4 loss per share $1.41
Tuesday, 14 Feb 2017 

Prothena Corporation Plc : Prothena Corporation Plc - Company expects full year 2017 net cash burn from operating and investing activities to be $160 to $170 million . Prothena reports fourth quarter and full year 2016 financial results, and provides financial guidance and research and development update . Q4 loss per share $1.41 . Q4 revenue $200,000 . Q4 revenue view $5.4 million -- Thomson Reuters I/B/E/S . Q4 earnings per share view $-1.12 -- Thomson Reuters I/B/E/S .Prothena Corporation Plc - Estimated 2017 net cash burn from operating, investing activities is primarily driven by estimated net loss of $177 to $191 million.  Full Article

Prothena Q4 loss per share $1.41
Tuesday, 14 Feb 2017 

Prothena Corporation Plc : Prothena corporation plc - expects full year 2017 net cash burn from operating and investing activities to be $160 to $170 million . Prothena reports fourth quarter and full year 2016 financial results, and provides financial guidance and research and development update . Q4 loss per share $1.41 . Q4 revenue $200,000 . Q4 revenue view $5.4 million -- Thomson Reuters I/B/E/S . Q4 earnings per share view $-1.12 -- Thomson Reuters I/B/E/S .Prothena corporation plc - estimated net loss of $177 to $191 million for fy.  Full Article

Prothena appoints Dr. Gene G. Kinney as CEO
Monday, 3 Oct 2016 

Prothena Corporation Plc : Prothena announces appointment of Dr. Gene G. Kinney as president, chief executive officer and director .Appointments come following passing of Prothena's co-founder, President and CEO, Dale B. Schenk.  Full Article

Prothena Corporation - CEO Dale B. Schenk, passed away
Friday, 30 Sep 2016 

Prothena Corporation Plc : Says Co-Founder, President and Chief Executive Officer, Dr. Dale B. Schenk, passed away .Says Board is meeting shortly regarding succession and an announcement will follow.  Full Article

Prothena says CEO Dr. Dale Schenk to take medical leave
Monday, 26 Sep 2016 

Prothena Corporation Plc : Prothena announces president and CEO Dr. Dale B. Schenk to take medical leave . Says Schenk will continue serving on Prothena's board of directors .Says co will be led by Gene Kinney.  Full Article

Prothena reports Net loss per share for Q2 $1.18
Tuesday, 2 Aug 2016 

Prothena Corporation Plc : Prothena reports second quarter 2016 financial results; provides research and development update . Net loss per share for q2 $1.18 . Projected full year 2016 net cash burn from operating and investing activities to be $118 to $128 million . Total revenue of $0.3 million for q2 compared to total revenue of $0.3 million for q2 of 2015 .Q2 earnings per share view $-0.91, revenue view $335710.00 -- Thomson Reuters I/B/E/S.  Full Article